APA (7th ed.) Citation

Tiruthani, K., Cruz‐Teran, C., Chan, J. F. W., Ma, A., McSweeney, M., Wolf, W., . . . Lai, S. K. (2024). Engineering a "muco‐trapping" ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19. Bioengineering & Translational Medicine, 9(4), 1. https://doi.org/10.1002/btm2.10650

Chicago Style (17th ed.) Citation

Tiruthani, Karthik, et al. "Engineering a "Muco‐trapping" ACE2‐immunoglobulin Hybrid with Picomolar Affinity as an Inhaled, Pan‐variant Immunotherapy for COVID‐19." Bioengineering & Translational Medicine 9, no. 4 (2024): 1. https://doi.org/10.1002/btm2.10650.

MLA (9th ed.) Citation

Tiruthani, Karthik, et al. "Engineering a "Muco‐trapping" ACE2‐immunoglobulin Hybrid with Picomolar Affinity as an Inhaled, Pan‐variant Immunotherapy for COVID‐19." Bioengineering & Translational Medicine, vol. 9, no. 4, 2024, p. 1, https://doi.org/10.1002/btm2.10650.